Trial Profile
A Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC) (MAGELLAN)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Carboplatin; Cisplatin; Danvatirsen; Gemcitabine; Oleclumab; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms MAGELLAN
- Sponsors AstraZeneca; AstraZeneca AB
- 26 Feb 2024 Planned End Date changed from 23 May 2023 to 26 Mar 2026.
- 29 May 2023 Planned End Date changed from 26 Mar 2026 to 23 May 2023.
- 29 May 2023 Planned primary completion date changed from 26 Mar 2026 to 23 May 2023.